Free cash flow remains deeply negative with quarterly outflows frequently exceeding $25 million, indicating that the company's current cash position of $48.5 million as of 2026Q1 provides a limited buffer for ongoing operations.
| Cash from Operations | -101.54M | -105.04M | -98.12M | -73.31M | -71.13M | -81.19M | -55.57M | -71.79M |
| Operating CF Margin % | - | -5154.17% | - | - | -4544.98% | -6428.35% | -3726.89% | -1160.29% |
| Operating CF Growth % | -14.48% | -7.05% | -33.85% | -3.06% | 12.39% | -46.11% | 22.59% | - |
| Net Income | -97.59M | -40.83M | -148.7M | -110.78M | -11.96M | -26.48M | -66.52M | -85.42M |
| Depreciation & Amortization | 5.07M | 5.33M | 7.19M | 7.72M | 8.21M | 8.24M | 8.43M | 6.75M |
| Stock-Based Compensation | 7.27M | 9.75M | 6.14M | 6.83M | 6.18M | 10.15M | 0 | 4.46M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.27M |
| Other Non-Cash Items | -1.15M | -55.9M | 36.94M | 16.35M | -74.59M | -72.54M | 4.89M | 6.25M |
| Working Capital Changes | -15.14M | -23.39M | 311K | 6.57M | 1.03M | -557K | -2.37M | 453K |
| Change in Receivables | 54K | -261K | 0 | 31K | 145K | -63K | 488K | -185K |
| Change in Inventory | -11.76M | -21.83M | 0 | 0 | 0 | 0 | 0 | -2.43M |
| Change in Payables | -42K | 973K | -1.96M | 4.81M | -509K | -197K | -889K | 2.43M |
| Cash from Investing | -831K | -884K | -1.57M | -173K | 4.84M | -8.22M | -268K | -8.13M |
| Capital Expenditures | -831K | -884K | -1.57M | -2.28M | -1.05M | -220K | -318K | -8.13M |
| CapEx % of Revenue | 41.22% | 43.38% | - | - | 66.96% | 17.42% | 21.33% | 131.32% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 50K | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 38.07M | 61.49M | 114.18M | 4.51M | -1.45M | 266.98M | 2.05M | -74K |
| Debt Issued (Net) | 37.07M | 36.38M | -2.58M | 5.7M | -1.98M | 27.93M | 1.75M | -1.29M |
| Equity Issued (Net) | 92.94M | 113.44M | 89.05M | 566K | 0 | 0 | 301K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -91.94M | -88.34M | 27.71M | -1.76M | 535K | 239.05M | 0 | 1.22M |
| Net Change in Cash | -64.45M | -44.44M | 14.49M | -69.18M | -67.73M | 177.57M | 39.93M | -79.99M |
| Free Cash Flow | -102.38M | -105.93M | -99.69M | -75.58M | -72.18M | -81.41M | -55.89M | -79.91M |
| FCF Margin % | -5078.17% | -5197.55% | - | - | -4611.95% | -6445.76% | -3748.22% | -1291.61% |
| FCF Growth % | -1.58% | -6.25% | -31.9% | -4.72% | 11.34% | -45.67% | 30.07% | - |
| FCF per Share | -0.52 | -0.67 | -0.84 | -0.73 | -0.70 | -2.04 | -4.49 | -3.97 |
| FCF Conversion (FCF/Net Income) | 1.05x | 2.57x | 0.66x | 0.66x | 5.94x | 3.07x | 0.84x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 2.67M | 1.12M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-commercial liquidity constraints
According to reported financial data, Humacyte's operating cash flow consistently trails net income, with an OCF/NI ratio that fluctuates wildly, including a 1.42 reading in 2026Q1, suggesting that accounting net income is a poor proxy for the actual cash resources consumed by the company's ongoing operations.
The persistent disconnect between net income and operating cash flow highlights the impact of non-cash items and the lack of a stable, revenue-generating core. Investors should monitor this divergence as it suggests that the company's reported profitability, when present, is largely disconnected from the actual cash-burn reality of its bioreactor manufacturing processes.
As reported in financial statements, Humacyte's free cash flow remains deeply negative, with quarterly outflows frequently exceeding $25 million, indicating that the company is currently in a high-burn phase as it attempts to scale its regenerative medicine technology toward a potential commercial launch.
The trajectory of free cash flow shows no signs of stabilization, reflecting the heavy reliance on external capital to fund clinical trials and manufacturing overhead. This trend suggests that the company remains entirely dependent on capital markets to bridge the gap between its current R&D-heavy cost structure and future commercial viability.
Based on the company's reported figures, working capital changes have been erratic, with a significant $9.6 million outflow in 2025Q1, suggesting that the timing of inventory build-up and vendor payments creates unpredictable pressure on the company's already limited cash reserves during this pre-commercial phase.
The variability in working capital suggests that the company is struggling to optimize its supply chain and cash conversion cycle as it prepares for potential commercialization. This volatility warrants further investigation into whether these outflows represent strategic inventory accumulation or inefficiencies in managing the complex logistics of bioengineered tissue production.
Data from recent filings indicates that Humacyte's cash flow statement obscures the true cost of production, as stock-based compensation and capitalized manufacturing costs may mask the underlying cash intensity required to maintain the LURE bioreactor system before the company achieves any meaningful commercial scale.
The reliance on non-cash adjustments to reconcile net income to operating cash flow suggests that the company's true operational burn may be higher than headline figures imply. Analysts should be cautious, as the capitalization of manufacturing costs could lead to future margin compression if those assets fail to generate the expected commercial throughput.
Quick answers to the most common questions about buying HUMA stock.
Humacyte, Inc. (HUMA) generated $-105.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Humacyte, Inc. (HUMA) reported negative free cash flow of $105.9M in 2025, indicating capital requirements exceeded cash from operations.
Humacyte, Inc. (HUMA) spent $0.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.